Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection
about
Conceptual framework for outcomes research studies of hepatitis C: an analytical reviewProfile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionStrategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomesDosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyDrug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-RitonavirPopulation Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesPharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIVTreatment of Chronic Hepatitis C Infection with Sofosbuvir-Based Regimens in a Commercially Insured Patient PopulationHCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection.Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.Viekira Pak Induced Fatal Lactic Acidosis: A Case Report of an Unusual Side EffectNovel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.The oncologic burden of hepatitis C virus infection: A clinical perspective.Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsIs response-guided therapy being applied in the clinical setting? The hepatitis C example.Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C.High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infectionSafety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4Era of direct acting anti-viral agents for the treatment of hepatitis C
P2860
Q26745582-7FEEFB9E-A2E5-40C8-A1FA-76AFBB14BA8EQ26775825-2B10747F-C24D-4A6B-8116-E85D1A5C72D7Q26777086-FD3F39B3-124A-41AE-BBBF-8B9EA8828B94Q28080752-485C9A75-4979-49AA-9B85-1E58D0836A73Q36438920-F1F8FE8F-3F4E-420D-A708-8D6AA7B1E255Q36445132-BB62F942-1760-4438-B802-3677715D11DDQ36806650-1528D609-DA48-4FEA-97E2-BB51318B556EQ36948115-17D7CE29-5DB4-4BC7-BDAA-C54027D3F460Q37055231-5D592BAE-39A4-47CB-9D86-C0B97C0CE8B6Q37441421-1D419ECA-124A-4677-9BAF-089A5E792D75Q37446584-4393DD7C-539C-41EB-A7F5-BD057DDA0BA6Q38836056-C1A8B458-92B5-40DE-8FF4-32855C7496DDQ38929010-A46E931C-0D83-4FA0-ACD6-904AD1A782A3Q39043731-5931EBA1-2329-4D14-9AF7-2220EC95ACF0Q39092977-26A95045-9533-450C-9E0E-A232C3DA1DFFQ39418450-B4E86552-27D8-4CF9-B09E-60B11CB40E04Q39862666-25FB9667-0B68-470E-9782-3B8ADA6FFCF7Q40108102-C607C925-3B22-4F07-AF72-B93F22D7326EQ40141719-52ABFD2B-A344-406A-B8B3-A8913A8D7625Q40829360-7DAD38F3-E042-4A27-BD50-F687BA0622EAQ41694415-70CEA749-EE3F-4023-982D-DCD4BCF742BDQ47567111-C29DEDD7-F9F1-4D57-87CC-CF2A1285713BQ58582162-1158A8F2-63CE-466F-AAD8-7B76843236B7Q58603882-6DCCA969-E094-476A-9609-A0C16B35CAE6
P2860
Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Viekira Pak (Ombitasvir, Parit ...... Chronic Hepatitis C Infection
@ast
Viekira Pak (Ombitasvir, Parit ...... Chronic Hepatitis C Infection
@en
type
label
Viekira Pak (Ombitasvir, Parit ...... Chronic Hepatitis C Infection
@ast
Viekira Pak (Ombitasvir, Parit ...... Chronic Hepatitis C Infection
@en
prefLabel
Viekira Pak (Ombitasvir, Parit ...... Chronic Hepatitis C Infection
@ast
Viekira Pak (Ombitasvir, Parit ...... Chronic Hepatitis C Infection
@en
P2860
P1476
Viekira Pak (Ombitasvir, Parit ...... Chronic Hepatitis C Infection
@en
P2093
Lisa A Raedler
P2860
P304
P433
Spec Feature
P577
2015-03-01T00:00:00Z